Zmax

Urethritis, Chancroid, Tonsillitis + 34 more

Treatment

32 FDA approvals

20 Active Studies for Zmax

What is Zmax

Azithromycin

The Generic name of this drug

Treatment Summary

Azithromycin is an antibiotic used to treat a wide range of infections, such as respiratory, enteric and genitourinary infections. It is related to erythromycin, but has a different chemical structure. Azithromycin was approved by the FDA in 1991. In March 2020, a small study conducted in France showed positive results when azithromycin was combined with an anti-malaria drug to treat COVID-19. However, more research is needed to confirm these results.

Zithromax

is the brand name

Zmax Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zithromax

Azithromycin

1994

541

Approved as Treatment by the FDA

Azithromycin, otherwise called Zithromax, is approved by the FDA for 32 uses including Bacterial Sinusitis and Sinusitis .

Bacterial Sinusitis

Sinusitis

Haemophilus Influenzae Infections

Genus Chlamydia

patients appropriate for oral therapy

Tonsillitis bacterial

genital ulcers caused by haemophilus ducreyi infection

Acute Otitis Media (AOM)

Streptococcus pyogenes

Streptococcal Pharyngitis

Tonsillitis streptococcal

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

Tonsillitis

Haemophilus ducreyi infection

Moraxella Catarrhalis Infection

Community Acquired Pneumonia (CAP)

Moraxella catarrhalis

ABDIC protocol

Adults

Streptococcus Pneumoniae Infections

Adult Patients

Genital Ulcer Disease (GUD)

Communicable Diseases

Staphylococcus (S.) Aureus Infection

Pneumococcal Infections

Pneumonia, Mycoplasma

Tonsillitis

Pediatric Patients

Otitis

Sore Throat

Streptococcus pyogenes

Streptococcus Agalactiae Infection

Effectiveness

How Zmax Affects Patients

Macrolides are a type of drug used to treat bacterial infections. They work by blocking the production of proteins that the bacteria need to survive. Azithromycin has additional benefits and is often used to help with chronic respiratory diseases.

How Zmax works in the body

Azithromycin is an antibiotic that works by preventing bacteria from producing proteins. It binds to the ribosomes of the bacterial cells, blocking their ability to create proteins that are necessary for them to survive and reproduce. This stops the spread of bacterial infections. Azithromycin is more effective than other antibiotics because it is more stable in low pH levels, so it stays in the body longer and can reach higher concentrations in tissues.

When to interrupt dosage

The suggested amount of Zmax is predicated on the diagnosed affliction, including Streptococcus Agalactiae Infection, Chlamydia trachomatis and Genus Chlamydia. The dosage is subject to the technique of delivery depicted in the table underneath.

Condition

Dosage

Administration

Streptococcus Agalactiae Infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Urethritis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chancroid

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Conjunctivitis, Bacterial

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Otitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chlamydia trachomatis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genus Chlamydia

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genital Ulcer Disease (GUD)

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Haemophilus ducreyi infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Streptococcus pyogenes

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Moraxella catarrhalis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Uterine Cervicitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Sinusitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Adult Patients

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Bacterial conjunctivitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Pneumonia, Mycoplasma

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Warnings

Zmax Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Jaundice, Obstructive

Do Not Combine

prior azithromycin use

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

There are 20 known major drug interactions with Zmax.

Common Zmax Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Asenapine.

Astemizole

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Astemizole.

Zmax Toxicity & Overdose Risk

The lethal dose of azithromycin for rats is greater than 2000mg/kg. Side effects may include heart problems, hearing loss, and liver or kidney damage. People with reduced liver function should be careful when taking azithromycin. Pregnant women should only take azithromycin if it is absolutely necessary, as it is unknown if the drug is passed to babies through milk. Long-term studies have not been done to determine if the drug causes cancer, but so far it has not been found to be mutagenic or to affect fertility.

image of a doctor in a lab doing drug, clinical research

Zmax Novel Uses: Which Conditions Have a Clinical Trial Featuring Zmax?

Currently, 9 active clinical trials are underway to assess the utility of Zmax in treating Moraxella Catarrhalis Infection, Staphylococcus (S.) Aureus Infection and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Sinusitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Staphylococcus (S.) Aureus Infection

2 Actively Recruiting

Phase 4, Phase 1

Conjunctivitis, Bacterial

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Moraxella catarrhalis

0 Actively Recruiting

Streptococcus Agalactiae Infection

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Uterine Cervicitis

0 Actively Recruiting

Genital Ulcer Disease (GUD)

0 Actively Recruiting

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Diarrhea

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Pediatric Patients

0 Actively Recruiting

Adult Patients

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Zmax Reviews: What are patients saying about Zmax?

5

Patient Review

1/5/2011

Zmax for Acute Bacterial Infection of the Sinuses

About an hour after taking this medication, I experienced diarrhea. This happened a few times throughout the night. Additionally, I had mild stomach cramps but nothing too severe. My mouth was also very dry; however, this could be due to the fact that I couldn't really breathe through my nose. The next day, I still experienced loose stool but no other symptoms.

5

Patient Review

3/25/2010

Zmax for Acute Bacterial Infection of the Sinuses

I only needed two days worth of this medication and I'm feeling almost back to normal. The slight dizziness is a manageable side effect.

4.7

Patient Review

3/19/2008

Zmax for Acute Bacterial Infection of the Sinuses

I experienced quite a bit of stomach pain and nausea while taking this medication.

4.7

Patient Review

9/17/2009

Zmax for Severe Sinusitis caused by Streptococcus Pneumoniae

Though it took a bit longer than I would've liked, this fever reducer really knocked out my fever quickly and effectively.

4.3

Patient Review

1/30/2011

Zmax for Acute Bacterial Infection of the Sinuses

I took the recommended oral dose yesterday with no issues, but I'm feeling pretty dizzy today.

4.3

Patient Review

3/30/2008

Zmax for Pneumonia caused by Bacteria

I liked that I only had to take this medication once, but unfortunately it made me feel very nauseous and gave me a headache (and some dizziness).

4

Patient Review

6/6/2008

Zmax for Acute Bacterial Infection of the Sinuses

I found this treatment really effective. I was a little bit dizzy but it wasn't anything serious. It's great to have something that works so quickly.

4

Patient Review

10/9/2011

Zmax for Acute Bacterial Infection of the Sinuses

I've been taking this for two days now to help with a sinus infection. The infection itself seems to be getting better, but I have experienced some serious gastrointestinal side effects, including vomiting and diarrhea. Additionally, I have felt mildly dizzy and lost my appetite.

4

Patient Review

11/5/2008

Zmax for Pneumonia caused by the Bacteria Chlamydia

I had a lot of stomach pain while taking this, but it eventually went away. It was nice only having to take it once, and it worked just as well as the z-pack.

3

Patient Review

12/1/2010

Zmax for Pneumonia caused by Bacteria

I followed the instructions to take the oral dose on an empty stomach, but I ended up vomiting uncontrollably for over an hour. It was so bad that I lost consciousness briefly. Three weeks later and pneumonia is much better, however, I've developed terrible side effects from the medication like persistent diarrhea, bloating, cramping, and blood in my stool. Do not recommend this medicine because of these harmful side effects!

3

Patient Review

12/15/2012

Zmax for Acute Bacterial Infection of the Sinuses

I started noticing negative effects after taking the last of my doctor-prescribed 10 tablets of 500mg each. I've been dealing with diarrhea, vomiting and nausea for the past four months now. Is there any relief?

3

Patient Review

11/13/2010

Zmax for Pneumonia caused by Bacteria

I threw up around an hour and a half after taking this medication, and then continued to vomit for another four hours. I followed the instructions by taking it on an empty stomach, but afterwards I felt much better.

2

Patient Review

11/10/2008

Zmax for Acute Bacterial Infection of the Sinuses

Unfortunately, this medication gave me severe stomach cramps and diarrhea. Additionally, after taking it for a few days, my sinus symptoms came back.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zmax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you use zMAX in diesel?

"Yes, zMAX can be used in both gasoline and diesel engines."

Answered by AI

What does zMAX do for your engine?

"It doesn't matter what year your vehicle is, it needs zMAX Micro-lubricant to disperse carbon build-up in your engine, fuel system and transmission. This helps improve performance, extend engine life and reduce emissions."

Answered by AI

Is there a zMAX?

"zMAX is a micro-lubricant that uses the fluids in your vehicle to get to internal parts where it soaks into metal to disperse harmful carbon build-up. Other products change the viscosity of the oil. zMAX doesn't need to do that. It works all on its own."

Answered by AI

Clinical Trials for Zmax

Image of Grady Memorial Hospital in Atlanta, United States.

Point-of-care Testing for Sexually Transmitted Infections

Any Age
Female
Atlanta, GA

The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting. The main questions it aims to answer are: * Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing? * What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care? * What are the costs and cost-effectiveness of POCTs compared with standard testing? Participants will: * Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing. * If diagnosed with an STI, complete a follow-up survey approximately one month later. * Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.

Waitlist Available
Has No Placebo

Grady Memorial Hospital

Kristin Wall, PhD

Image of Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University in Toronto, Canada.

White Potatoes for Glycemic Responses

18 - 65
All Sexes
Toronto, Canada

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Recruiting
Has No Placebo

Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University

Have you considered Zmax clinical trials?

We made a collection of clinical trials featuring Zmax, we think they might fit your search criteria.
Go to Trials
Image of Washington University in St. Louis in St Louis, United States.

Adapted HARP for Falls Prevention

45 - 64
All Sexes
St Louis, MO

The Home Hazard Removal Program (HARP) is an effective fall prevention intervention program which targets home hazard identification/removal. In this study the investigators will examine the effectiveness and implementation potential of HARP, adapted for PwD. Investigators will conduct a pilot randomized control trial (RCT) to test the implementation, cost, and preliminary efficacy of an adapted version of HARP for community-dwelling PwD. The single-blinded feasibility RCT will randomize 40 participants to treatment (adapted HARP) and 40 to a waitlist control group. Data on specific types of fall hazards and resulting home modifications as well as falls and fall-related injuries (collected monthly over 12 months) and fear of falling (collected at baseline and 12 months) will inform the preliminary efficacy of adapted HARP among PwD. To ensure usefulness, relevance, and broad dissemination of findings, the investigators will adopt a "designing for implementation and dissemination" approach. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework will guide intervention adaptation, trial design, and future implementation. The Practical Robust Implementation and Sustainability Model (PRISM) guides study development by identifying multi-level contextual factors hypothesized to affect the RE-AIM outcomes.

Recruiting
Has No Placebo

Washington University in St. Louis

Susan L Stark, PhD

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Image of USC Voice Center in Arcadia, United States.

Voice Therapy for Age-Related Voice Change

18+
All Sexes
Arcadia, CA

This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors. The two primary hypotheses are: 1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face? 2. Can online therapy be a more accessible way for older adults to get help for their voice problems? Adults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through: * Changes in voice function * Patient reports about their voice * Scientific measurements of voice quality * Patient satisfaction with treatment * Impact on quality of life The results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.

Waitlist Available
Has No Placebo

USC Voice Center (+3 Sites)

Aaron Rothbart, PhD

Have you considered Zmax clinical trials?

We made a collection of clinical trials featuring Zmax, we think they might fit your search criteria.
Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA

The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.

Recruiting
Has No Placebo

Loma Linda University Medical Center Troesh Medical Campus

Elizabeth Johnston Taylor, PhD, FAAN

Have you considered Zmax clinical trials?

We made a collection of clinical trials featuring Zmax, we think they might fit your search criteria.
Go to Trials